Processa Pharmaceuticals, Inc.

PCSA

US74275C3043

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:00:00 29/06/2024 am IST			5-day change	1st Jan Change
2.24 ^USD	+7.18%		+14.29%	-66.53%

11/06	Processa Pharmaceuticals, Inc. Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1B Dose-Escalating Trial with Ngc-Cap in Gastrointestinal Cancer	CI
07/06	Top Premarket Decliners	MT

Processa Pharmaceuticals, Inc. Elects Khoso Baluch as Director

July 15, 2022 at 01:22 am IST

Processa Pharmaceuticals, Inc. at its AGM held on July 11, 2022, elected Khoso Baluch as director.

Latest news about Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals, Inc. Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1B Dose-Escalating Trial with Ngc-Cap in Gastrointestinal Cancer	11/06	CI
Top Premarket Decliners	07/06	MT
Processa Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	11/05	CI
Processa Pharmaceuticals, Inc. Names Steven Cha as Senior Vice President of Clinical Research	30/04	CI
Certain Common Warrants of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024.	30/04	CI
Certain Restricted Stock Units of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024.	30/04	CI
Certain Options of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024.	30/04	CI
Certain Common Stock of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024.	30/04	CI
Top Premarket Decliners	26/04	MT
Top Midday Gainers	25/04	MT
HC Wainwright Starts Processa Pharmaceuticals With Buy Rating, $8 Price Target	25/04	MT
Processa Pharmaceuticals, Inc. Presents Two Abstracts At the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1B Trial	11/04	CI
Processa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	30/03	CI
Sector Update: Health Care Stocks Stronger Late Afternoon	27/01	MT
Top Midday Decliners	27/01	MT
Sector Update: Health Care Stocks Higher Friday Afternoon	27/01	MT
Processa Pharmaceuticals Prices $7 Million Common Stock Offering	26/01	MT
Sector Update: Health Care Stocks Softer Late Afternoon	26/01	MT
Top Midday Gainers	26/01	MT
Processa Pharmaceuticals Shares More Than Double After Completing Safety Evaluation of Cancer Treatment	25/01	DJ
Processa Pharmaceuticals, Inc. Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses	25/01	CI
Processa Pharmaceuticals Proposes Equity Offering	23/01	MT
Sector Update: Health Care Stocks Steady Late Afternoon	20/01	MT
Sector Update: Health Care	20/01	MT
Processa Plans to Expand NGC-Cap Program Into Breast Cancer; Shares Soar	20/01	MT

Chart Processa Pharmaceuticals, Inc.

Duration

Period

More charts

Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on utilizing its regulatory science approach, including the principles associated with food and drug administration (FDAâs) Project Optimus Oncology initiative and the related FDA Draft Guidance, in the development of Next Generation Chemotherapy (NGC) oncology drug products. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine, resulting in a positive response in gemcitabine patients and some gemcitabine treatment-resistant patients. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38).

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.24 USD

Average target price

6 USD

Spread / Average Target

+167.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PROCESSA PHARMACEUTICALS, INC.	-66.53%	64.02L
ELI LILLY AND COMPANY	+55.32%	82TCr
NOVO NORDISK A/S	+44.05%	64TCr
JOHNSON & JOHNSON	-6.75%	35TCr
MERCK & CO., INC.	+13.56%	31TCr
ABBVIE INC.	+10.68%	30TCr
ASTRAZENECA PLC	+16.57%	24TCr
NOVARTIS AG	+13.31%	22TCr
AMGEN INC.	+8.48%	17TCr
PFIZER, INC.	-2.81%	16TCr

Other Pharmaceuticals